Orphan Drug Designations are declining, says market analysis
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
List view / Grid view
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
The UK government has changed the restrictions on importing cannabis-based medicine products into the country, allowing wholesalers to bring in larger quantities.
The FDA has released a statement, announcing that the US is experiencing its first shortage as a result of the effects of COVID-19.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
Eliminating expensive catalysts, researchers have shown it is possible to transfer nitrogen atoms to unactivated olefins for the production of aziridines.
The MHRA has issued two alerts, one for incorrect maximum daily dosage of Ibuprofen 400mg and a second for missing safety information about Oxylan Prolonged-release tablets.
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
NICE has given its positive opinion to lenalidomide in combination with rituximab as a 'chemotherapy-free' treatment for lymphoma.
Ranitidine tablets have been recalled due to the possibility of the products containing unacceptable levels of NDMA.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB collaboration) was devised to create transformative regimens for TB treatment, irrespective of drug resistance status.
Two companies have announced their partnership to work on the 3D printing of tablets for use in clinical trials.
Chemspec Europe, the International Exhibition for Fine and Speciality Chemicals, returns to Cologne for its 35th edition. From 27 – 28 May 2020, renowned manufacturers, suppliers and distributors of fine and speciality chemicals present their latest products, services and research findings to a dedicated audience of industry experts.
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Researchers have shown that the CALB lipase enzyme can be used to produce macrocycles of a specified shape using biocatalysis.